 James Falko
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperlipidemias | 8 | 2006 | 121 | 0.620 |
Why?
| | Hyperlipoproteinemia Type I | 1 | 2018 | 7 | 0.620 |
Why?
| | Alcohol Abstinence | 1 | 2018 | 10 | 0.620 |
Why?
| | Plasmapheresis | 1 | 2018 | 21 | 0.620 |
Why?
| | Diet, Fat-Restricted | 1 | 2018 | 73 | 0.600 |
Why?
| | Diabetic Angiopathies | 4 | 2005 | 246 | 0.520 |
Why?
| | Anticholesteremic Agents | 4 | 2012 | 129 | 0.520 |
Why?
| | Diabetic Neuropathies | 2 | 2005 | 78 | 0.460 |
Why?
| | Hyperlipoproteinemia Type II | 3 | 2016 | 26 | 0.450 |
Why?
| | Metabolic Syndrome | 3 | 2008 | 320 | 0.420 |
Why?
| | Lipoproteins | 10 | 1997 | 159 | 0.370 |
Why?
| | Hypothyroidism | 4 | 2018 | 65 | 0.360 |
Why?
| | Diabetes Mellitus, Type 2 | 12 | 2005 | 2087 | 0.360 |
Why?
| | Cardiovascular Diseases | 3 | 2012 | 1726 | 0.330 |
Why?
| | Cholesterol, LDL | 9 | 2012 | 307 | 0.300 |
Why?
| | Lipoproteins, LDL | 11 | 1997 | 127 | 0.290 |
Why?
| | Hyperthyroidism | 8 | 1997 | 26 | 0.280 |
Why?
| | Hypolipidemic Agents | 3 | 2006 | 86 | 0.270 |
Why?
| | Fenofibrate | 2 | 2003 | 24 | 0.270 |
Why?
| | Lipoproteins, HDL | 11 | 2008 | 76 | 0.250 |
Why?
| | Insulin | 16 | 1991 | 2080 | 0.230 |
Why?
| | Blood Component Removal | 2 | 2016 | 26 | 0.230 |
Why?
| | Pancreatitis | 5 | 2018 | 105 | 0.220 |
Why?
| | Rhabdomyolysis | 1 | 2003 | 16 | 0.220 |
Why?
| | Dyslipidemias | 1 | 2005 | 153 | 0.220 |
Why?
| | Blood Glucose | 20 | 2008 | 1827 | 0.220 |
Why?
| | Dietary Fats | 5 | 1996 | 287 | 0.220 |
Why?
| | Diagnosis, Differential | 8 | 2018 | 1331 | 0.210 |
Why?
| | Triglycerides | 11 | 2008 | 467 | 0.210 |
Why?
| | Hypertriglyceridemia | 2 | 2018 | 34 | 0.210 |
Why?
| | Cholesterol, HDL | 8 | 2005 | 184 | 0.200 |
Why?
| | Cholesterol | 12 | 2006 | 368 | 0.180 |
Why?
| | Thyroid Neoplasms | 6 | 1998 | 271 | 0.170 |
Why?
| | Apolipoproteins | 6 | 1984 | 36 | 0.170 |
Why?
| | Xanthomatosis | 2 | 2018 | 10 | 0.160 |
Why?
| | Humans | 88 | 2018 | 114043 | 0.160 |
Why?
| | Hepatomegaly | 1 | 2018 | 2 | 0.160 |
Why?
| | Hyperlipoproteinemia Type IV | 3 | 1996 | 3 | 0.160 |
Why?
| | Splenomegaly | 1 | 2018 | 16 | 0.160 |
Why?
| | Nephrotic Syndrome | 1 | 2018 | 24 | 0.150 |
Why?
| | Dietary Carbohydrates | 4 | 1986 | 138 | 0.150 |
Why?
| | Lipoprotein Lipase | 1 | 2018 | 54 | 0.150 |
Why?
| | Thyroid Nodule | 1 | 1998 | 45 | 0.150 |
Why?
| | Carcinoma, Papillary | 1 | 1998 | 74 | 0.150 |
Why?
| | Diabetes Mellitus | 6 | 2018 | 898 | 0.140 |
Why?
| | Lipoproteins, VLDL | 7 | 1984 | 21 | 0.140 |
Why?
| | Endocrinology | 1 | 2018 | 71 | 0.140 |
Why?
| | Abdominal Pain | 1 | 2018 | 134 | 0.140 |
Why?
| | Glyburide | 3 | 1985 | 35 | 0.140 |
Why?
| | Arteriosclerosis | 4 | 1997 | 82 | 0.140 |
Why?
| | Gastrointestinal Hormones | 4 | 1982 | 8 | 0.140 |
Why?
| | Genetic Therapy | 1 | 2018 | 256 | 0.140 |
Why?
| | Adenoma, Islet Cell | 3 | 1984 | 10 | 0.130 |
Why?
| | C-Peptide | 7 | 1986 | 138 | 0.130 |
Why?
| | Insulinoma | 3 | 1984 | 29 | 0.130 |
Why?
| | Cost of Illness | 1 | 2018 | 254 | 0.130 |
Why?
| | Female | 67 | 2016 | 59325 | 0.130 |
Why?
| | Lipids | 6 | 2006 | 564 | 0.130 |
Why?
| | Middle Aged | 41 | 2016 | 26605 | 0.130 |
Why?
| | Gastric Inhibitory Polypeptide | 4 | 1986 | 14 | 0.130 |
Why?
| | Recurrence | 1 | 2018 | 925 | 0.130 |
Why?
| | Lipoprotein(a) | 1 | 2016 | 51 | 0.120 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1996 | 122 | 0.120 |
Why?
| | Obesity | 7 | 2010 | 2505 | 0.120 |
Why?
| | Niacin | 2 | 2005 | 18 | 0.120 |
Why?
| | Sucrose | 3 | 1986 | 92 | 0.110 |
Why?
| | Glucose Tolerance Test | 5 | 1987 | 343 | 0.110 |
Why?
| | Alcoholism | 2 | 2018 | 710 | 0.110 |
Why?
| | Adult | 46 | 2008 | 30375 | 0.100 |
Why?
| | Receptors, LDL | 1 | 2012 | 38 | 0.100 |
Why?
| | Thrombosis | 1 | 2016 | 295 | 0.100 |
Why?
| | Glucose | 7 | 1986 | 899 | 0.100 |
Why?
| | Hyperparathyroidism | 3 | 1984 | 12 | 0.100 |
Why?
| | Male | 50 | 2010 | 55396 | 0.100 |
Why?
| | Plaque, Atherosclerotic | 1 | 2012 | 46 | 0.100 |
Why?
| | Drug Design | 1 | 2012 | 147 | 0.100 |
Why?
| | Pheochromocytoma | 2 | 1990 | 54 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 1996 | 430 | 0.090 |
Why?
| | Adrenal Gland Neoplasms | 2 | 1990 | 81 | 0.090 |
Why?
| | Hyperaldosteronism | 1 | 1990 | 8 | 0.090 |
Why?
| | Hypercalcemia | 2 | 1984 | 19 | 0.090 |
Why?
| | Splenic Neoplasms | 1 | 1990 | 2 | 0.090 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 1990 | 28 | 0.090 |
Why?
| | Multiple Endocrine Neoplasia | 1 | 1990 | 6 | 0.090 |
Why?
| | Pancreatic Neoplasms | 4 | 1984 | 721 | 0.090 |
Why?
| | Coronary Artery Disease | 2 | 2006 | 611 | 0.090 |
Why?
| | Hyperlipoproteinemia Type III | 2 | 1980 | 3 | 0.090 |
Why?
| | Musculoskeletal Diseases | 1 | 2010 | 54 | 0.080 |
Why?
| | Age Factors | 3 | 2012 | 2885 | 0.080 |
Why?
| | Fructose | 3 | 1987 | 100 | 0.080 |
Why?
| | Lipid Metabolism | 3 | 2006 | 441 | 0.070 |
Why?
| | Quality of Life | 1 | 2018 | 2343 | 0.070 |
Why?
| | Diuretics | 2 | 1986 | 64 | 0.070 |
Why?
| | Physical Therapy Modalities | 1 | 2010 | 265 | 0.070 |
Why?
| | Indapamide | 1 | 1986 | 1 | 0.070 |
Why?
| | Metoclopramide | 1 | 1986 | 16 | 0.070 |
Why?
| | Apoproteins | 1 | 1986 | 12 | 0.070 |
Why?
| | Stomach Diseases | 1 | 1986 | 19 | 0.070 |
Why?
| | Optic Atrophy | 1 | 1986 | 10 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 1990 | 504 | 0.070 |
Why?
| | Cyclosporins | 1 | 1986 | 58 | 0.070 |
Why?
| | Community Health Services | 1 | 2008 | 212 | 0.060 |
Why?
| | Hyponatremia | 1 | 1986 | 37 | 0.060 |
Why?
| | Disease Progression | 1 | 2012 | 2371 | 0.060 |
Why?
| | Shoes | 1 | 2005 | 21 | 0.060 |
Why?
| | Weight Loss | 2 | 2010 | 642 | 0.060 |
Why?
| | Muscular Diseases | 1 | 1986 | 104 | 0.060 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 1979 | 220 | 0.060 |
Why?
| | Diabetic Foot | 1 | 2005 | 22 | 0.060 |
Why?
| | Heptanoic Acids | 1 | 2005 | 60 | 0.060 |
Why?
| | Sulfonylurea Compounds | 1 | 1985 | 44 | 0.060 |
Why?
| | Medical History Taking | 1 | 2005 | 115 | 0.060 |
Why?
| | Radionuclide Imaging | 6 | 1998 | 115 | 0.060 |
Why?
| | Deafness | 1 | 1986 | 77 | 0.060 |
Why?
| | Pain | 1 | 2010 | 701 | 0.060 |
Why?
| | Ultrasonography | 2 | 1984 | 635 | 0.060 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1984 | 51 | 0.060 |
Why?
| | Pyrroles | 1 | 2005 | 181 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2005 | 926 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 4 | 1991 | 3254 | 0.060 |
Why?
| | Diabetes Complications | 1 | 2005 | 208 | 0.060 |
Why?
| | Physical Examination | 1 | 2005 | 221 | 0.060 |
Why?
| | Iodine Radioisotopes | 3 | 1998 | 126 | 0.060 |
Why?
| | Time Factors | 8 | 2006 | 6077 | 0.050 |
Why?
| | Fish Oils | 1 | 2003 | 21 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2005 | 362 | 0.050 |
Why?
| | Ezetimibe | 1 | 2003 | 24 | 0.050 |
Why?
| | Azetidines | 1 | 2003 | 31 | 0.050 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1984 | 160 | 0.050 |
Why?
| | Aged | 13 | 2006 | 18969 | 0.050 |
Why?
| | Coronary Disease | 1 | 2005 | 348 | 0.050 |
Why?
| | Furosemide | 2 | 1986 | 31 | 0.050 |
Why?
| | Hypertension | 3 | 1986 | 1052 | 0.050 |
Why?
| | 1-Propanol | 1 | 1982 | 1 | 0.050 |
Why?
| | Heart Diseases | 1 | 2005 | 329 | 0.050 |
Why?
| | Mutation | 1 | 2012 | 3338 | 0.050 |
Why?
| | Particle Size | 1 | 2003 | 317 | 0.050 |
Why?
| | Patient Care Team | 1 | 2006 | 517 | 0.050 |
Why?
| | Osteoporosis | 1 | 1985 | 224 | 0.050 |
Why?
| | Exercise Therapy | 1 | 2005 | 351 | 0.050 |
Why?
| | Apolipoproteins C | 2 | 1982 | 6 | 0.050 |
Why?
| | Empty Sella Syndrome | 1 | 1981 | 1 | 0.050 |
Why?
| | Metrizamide | 1 | 1981 | 1 | 0.050 |
Why?
| | Copper | 2 | 1997 | 99 | 0.040 |
Why?
| | Calcium | 2 | 1984 | 1089 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 1986 | 538 | 0.040 |
Why?
| | Hyperlipoproteinemia Type V | 1 | 1979 | 1 | 0.040 |
Why?
| | Hyperlipoproteinemias | 1 | 1979 | 6 | 0.040 |
Why?
| | Ethinyl Estradiol | 1 | 1979 | 17 | 0.040 |
Why?
| | Drug Therapy, Combination | 4 | 1991 | 949 | 0.040 |
Why?
| | Sodium Pertechnetate Tc 99m | 2 | 1998 | 6 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 373 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 5 | 1993 | 2272 | 0.040 |
Why?
| | Central Nervous System Diseases | 1 | 1979 | 60 | 0.040 |
Why?
| | Insulin Infusion Systems | 1 | 1982 | 298 | 0.040 |
Why?
| | Primary Health Care | 2 | 2006 | 1502 | 0.040 |
Why?
| | Sodium Iodide | 1 | 1998 | 3 | 0.040 |
Why?
| | Medicine, Ayurvedic | 1 | 1997 | 1 | 0.040 |
Why?
| | Pancreatic Juice | 1 | 1977 | 2 | 0.040 |
Why?
| | Water-Electrolyte Balance | 1 | 1977 | 26 | 0.040 |
Why?
| | Oxidation-Reduction | 2 | 1997 | 917 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 1998 | 158 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 1985 | 1011 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 1997 | 139 | 0.040 |
Why?
| | Phytotherapy | 1 | 1997 | 67 | 0.040 |
Why?
| | Drug Resistance | 1 | 1997 | 158 | 0.030 |
Why?
| | Thyroid Gland | 3 | 1982 | 85 | 0.030 |
Why?
| | Acidosis, Renal Tubular | 1 | 1976 | 5 | 0.030 |
Why?
| | Diazoxide | 1 | 1977 | 22 | 0.030 |
Why?
| | Stomach | 2 | 1983 | 102 | 0.030 |
Why?
| | Adolescent | 12 | 1998 | 17800 | 0.030 |
Why?
| | Body Mass Index | 3 | 2010 | 1957 | 0.030 |
Why?
| | Pituitary Neoplasms | 3 | 1982 | 156 | 0.030 |
Why?
| | Oils | 2 | 1976 | 19 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 2b | 1 | 1996 | 6 | 0.030 |
Why?
| | Proto-Oncogenes | 1 | 1996 | 26 | 0.030 |
Why?
| | Carcinoma, Medullary | 1 | 1996 | 14 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 1996 | 8 | 0.030 |
Why?
| | Magnesium Deficiency | 1 | 1976 | 2 | 0.030 |
Why?
| | Polycythemia | 1 | 1976 | 23 | 0.030 |
Why?
| | Procainamide | 1 | 1975 | 5 | 0.030 |
Why?
| | Reference Values | 1 | 1997 | 739 | 0.030 |
Why?
| | Hypocalcemia | 1 | 1976 | 30 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 1982 | 637 | 0.030 |
Why?
| | Bone Resorption | 1 | 1976 | 73 | 0.030 |
Why?
| | Pancreas | 1 | 1977 | 276 | 0.030 |
Why?
| | Anemia | 1 | 1976 | 143 | 0.030 |
Why?
| | Pancreatic Cyst | 1 | 1975 | 46 | 0.030 |
Why?
| | Graves Disease | 3 | 1985 | 34 | 0.030 |
Why?
| | Antioxidants | 1 | 1997 | 529 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 1996 | 337 | 0.030 |
Why?
| | Orbital Pseudotumor | 1 | 1993 | 3 | 0.030 |
Why?
| | Postpartum Period | 1 | 1996 | 275 | 0.030 |
Why?
| | Hypopituitarism | 1 | 1993 | 15 | 0.030 |
Why?
| | Animals | 2 | 2012 | 31565 | 0.030 |
Why?
| | Cranial Nerve Diseases | 1 | 1993 | 42 | 0.030 |
Why?
| | Paralysis | 1 | 1993 | 66 | 0.030 |
Why?
| | Fasting | 3 | 2006 | 242 | 0.030 |
Why?
| | Cholestasis | 1 | 1975 | 225 | 0.020 |
Why?
| | Cohort Studies | 3 | 2006 | 4883 | 0.020 |
Why?
| | Isoelectric Focusing | 3 | 1982 | 33 | 0.020 |
Why?
| | Patient Education as Topic | 2 | 2006 | 666 | 0.020 |
Why?
| | Thyrotropin | 2 | 1982 | 100 | 0.020 |
Why?
| | Sex Factors | 2 | 2006 | 1706 | 0.020 |
Why?
| | Octreotide | 1 | 1991 | 25 | 0.020 |
Why?
| | Androgen-Insensitivity Syndrome | 1 | 1990 | 5 | 0.020 |
Why?
| | Double-Blind Method | 2 | 1985 | 1656 | 0.020 |
Why?
| | Diet, Diabetic | 2 | 1987 | 33 | 0.020 |
Why?
| | Peptides | 1 | 1975 | 848 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2010 | 46 | 0.020 |
Why?
| | Body Weight | 2 | 1986 | 868 | 0.020 |
Why?
| | Hypoglycemia | 2 | 1984 | 386 | 0.020 |
Why?
| | United States | 2 | 2005 | 12137 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 1977 | 932 | 0.020 |
Why?
| | Risk Factors | 3 | 2008 | 8614 | 0.020 |
Why?
| | Pregnancy | 2 | 1996 | 5499 | 0.020 |
Why?
| | Ketone Bodies | 2 | 1991 | 15 | 0.020 |
Why?
| | Brain | 1 | 1981 | 2355 | 0.020 |
Why?
| | Secretory Rate | 2 | 1980 | 16 | 0.020 |
Why?
| | Technetium | 2 | 1981 | 8 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 1836 | 0.020 |
Why?
| | Treatment Outcome | 3 | 2008 | 9049 | 0.020 |
Why?
| | Thyroxine | 2 | 1981 | 57 | 0.020 |
Why?
| | Adenoma | 2 | 1982 | 187 | 0.020 |
Why?
| | Pain Measurement | 1 | 2010 | 441 | 0.020 |
Why?
| | Ohio | 1 | 2008 | 135 | 0.020 |
Why?
| | Body Size | 1 | 2008 | 90 | 0.020 |
Why?
| | Pain Management | 1 | 2010 | 285 | 0.020 |
Why?
| | Sweetening Agents | 1 | 1987 | 37 | 0.020 |
Why?
| | Suppositories | 1 | 1986 | 3 | 0.020 |
Why?
| | Gastric Emptying | 1 | 1986 | 39 | 0.020 |
Why?
| | Demeclocycline | 1 | 1986 | 3 | 0.020 |
Why?
| | Ticlopidine | 1 | 2006 | 54 | 0.020 |
Why?
| | Drug Administration Schedule | 2 | 2005 | 714 | 0.020 |
Why?
| | Fitness Centers | 1 | 2006 | 3 | 0.020 |
Why?
| | Carbohydrate Metabolism | 1 | 1986 | 48 | 0.020 |
Why?
| | Electrolytes | 1 | 1986 | 55 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2008 | 12521 | 0.020 |
Why?
| | Acute Disease | 3 | 1982 | 907 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 1986 | 104 | 0.020 |
Why?
| | Carcinoembryonic Antigen | 1 | 1985 | 38 | 0.020 |
Why?
| | Lung Neoplasms | 2 | 1990 | 2159 | 0.020 |
Why?
| | Premenstrual Syndrome | 1 | 1985 | 27 | 0.020 |
Why?
| | Atrophy | 1 | 1986 | 152 | 0.020 |
Why?
| | Infant, Newborn | 1 | 1996 | 5038 | 0.020 |
Why?
| | Decalcification, Pathologic | 1 | 1985 | 1 | 0.020 |
Why?
| | Anthropometry | 1 | 2006 | 183 | 0.020 |
Why?
| | Fibrous Dysplasia of Bone | 1 | 1985 | 5 | 0.020 |
Why?
| | Osteomalacia | 1 | 1985 | 4 | 0.020 |
Why?
| | Sodium Chloride | 1 | 1986 | 133 | 0.020 |
Why?
| | Placebos | 1 | 1985 | 197 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1990 | 850 | 0.020 |
Why?
| | Cost-Benefit Analysis | 2 | 1984 | 544 | 0.020 |
Why?
| | Blood Protein Electrophoresis | 1 | 1984 | 7 | 0.010 |
Why?
| | Pentamidine | 1 | 1984 | 3 | 0.010 |
Why?
| | Insulin Antagonists | 1 | 1984 | 6 | 0.010 |
Why?
| | Probability | 1 | 2005 | 286 | 0.010 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2006 | 286 | 0.010 |
Why?
| | Amidines | 1 | 1984 | 16 | 0.010 |
Why?
| | Thyroid Diseases | 1 | 1984 | 31 | 0.010 |
Why?
| | Patient Participation | 1 | 2008 | 348 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1984 | 360 | 0.010 |
Why?
| | Parathyroid Neoplasms | 1 | 1984 | 13 | 0.010 |
Why?
| | Palliative Care | 1 | 1990 | 641 | 0.010 |
Why?
| | Exercise Tolerance | 1 | 2005 | 212 | 0.010 |
Why?
| | Adrenal Gland Diseases | 1 | 1983 | 6 | 0.010 |
Why?
| | Blood Proteins | 1 | 1985 | 222 | 0.010 |
Why?
| | Program Evaluation | 1 | 2008 | 820 | 0.010 |
Why?
| | Parathyroid Hormone | 1 | 1984 | 96 | 0.010 |
Why?
| | Abortion, Induced | 1 | 1984 | 71 | 0.010 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2006 | 395 | 0.010 |
Why?
| | Diet | 1 | 2010 | 1080 | 0.010 |
Why?
| | Pancreatectomy | 1 | 1984 | 167 | 0.010 |
Why?
| | Chromatography | 1 | 1982 | 23 | 0.010 |
Why?
| | Nicotinic Acids | 1 | 1982 | 6 | 0.010 |
Why?
| | Administration, Oral | 2 | 1984 | 725 | 0.010 |
Why?
| | Lymphoma | 1 | 1983 | 176 | 0.010 |
Why?
| | Gastrins | 1 | 1982 | 8 | 0.010 |
Why?
| | Risk | 1 | 1985 | 810 | 0.010 |
Why?
| | Diabetes Insipidus | 1 | 1982 | 7 | 0.010 |
Why?
| | Hemoglobin A | 1 | 1982 | 21 | 0.010 |
Why?
| | Patient Compliance | 1 | 2006 | 524 | 0.010 |
Why?
| | Prevalence | 1 | 2008 | 2247 | 0.010 |
Why?
| | Adenoma, Chromophobe | 1 | 1981 | 1 | 0.010 |
Why?
| | Motivation | 1 | 2006 | 488 | 0.010 |
Why?
| | Alcoholic Intoxication | 1 | 1982 | 59 | 0.010 |
Why?
| | Radioimmunoassay | 2 | 1986 | 161 | 0.010 |
Why?
| | Survival Rate | 1 | 2005 | 1638 | 0.010 |
Why?
| | Desipramine | 1 | 1981 | 9 | 0.010 |
Why?
| | Mitral Valve Prolapse | 1 | 1981 | 8 | 0.010 |
Why?
| | Tomography, X-Ray | 1 | 1981 | 4 | 0.010 |
Why?
| | Thyroid Function Tests | 1 | 1981 | 11 | 0.010 |
Why?
| | Parotid Gland | 1 | 1980 | 24 | 0.010 |
Why?
| | Triiodothyronine | 1 | 1981 | 42 | 0.010 |
Why?
| | Hyperphagia | 1 | 1980 | 28 | 0.010 |
Why?
| | Apolipoprotein C-II | 1 | 1980 | 1 | 0.010 |
Why?
| | Food | 1 | 1982 | 160 | 0.010 |
Why?
| | Apolipoprotein C-III | 1 | 1980 | 13 | 0.010 |
Why?
| | Creatinine | 1 | 1982 | 424 | 0.010 |
Why?
| | Eating | 1 | 1983 | 344 | 0.010 |
Why?
| | Pseudomonas Infections | 1 | 1982 | 184 | 0.010 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 1982 | 180 | 0.010 |
Why?
| | Exercise | 1 | 2010 | 1642 | 0.010 |
Why?
| | Infarction | 1 | 1979 | 12 | 0.010 |
Why?
| | Apolipoproteins E | 1 | 1980 | 80 | 0.010 |
Why?
| | Cerebral Infarction | 1 | 1979 | 39 | 0.010 |
Why?
| | Lipolysis | 1 | 1979 | 39 | 0.010 |
Why?
| | Spinal Cord Diseases | 1 | 1979 | 38 | 0.010 |
Why?
| | Feeding and Eating Disorders | 1 | 1980 | 103 | 0.010 |
Why?
| | Clofibrate | 1 | 1979 | 4 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 1985 | 787 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1985 | 1257 | 0.010 |
Why?
| | Cerebral Arteries | 1 | 1979 | 55 | 0.010 |
Why?
| | Prospective Studies | 1 | 2010 | 6195 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 1981 | 282 | 0.010 |
Why?
| | Radiography | 1 | 1981 | 803 | 0.010 |
Why?
| | Heparin | 1 | 1979 | 225 | 0.010 |
Why?
| | Ambulatory Care | 1 | 1982 | 479 | 0.010 |
Why?
| | Depressive Disorder | 1 | 1981 | 330 | 0.010 |
Why?
| | Lipid Peroxides | 1 | 1997 | 9 | 0.010 |
Why?
| | Thiobarbituric Acid Reactive Substances | 1 | 1997 | 20 | 0.010 |
Why?
| | Secretin | 1 | 1977 | 4 | 0.010 |
Why?
| | Methods | 1 | 1977 | 57 | 0.010 |
Why?
| | Bile | 1 | 1977 | 26 | 0.010 |
Why?
| | Duodenum | 1 | 1977 | 62 | 0.010 |
Why?
| | Bilirubin | 1 | 1977 | 88 | 0.010 |
Why?
| | Intubation, Gastrointestinal | 1 | 1977 | 54 | 0.010 |
Why?
| | Intestinal Absorption | 1 | 1977 | 93 | 0.010 |
Why?
| | Erythrocytes | 1 | 1981 | 568 | 0.010 |
Why?
| | Hypercholesterolemia | 1 | 1997 | 90 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2005 | 4392 | 0.010 |
Why?
| | Sodium | 1 | 1977 | 184 | 0.010 |
Why?
| | Rats | 1 | 1984 | 4913 | 0.010 |
Why?
| | Risk Assessment | 1 | 2005 | 2958 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1996 | 25 | 0.010 |
Why?
| | Hematocrit | 1 | 1976 | 86 | 0.010 |
Why?
| | Tetany | 1 | 1976 | 3 | 0.010 |
Why?
| | Evaluation Studies as Topic | 2 | 1987 | 167 | 0.010 |
Why?
| | Magnesium Sulfate | 1 | 1976 | 16 | 0.010 |
Why?
| | Calcification, Physiologic | 1 | 1976 | 34 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 1996 | 155 | 0.010 |
Why?
| | Cholangiography | 1 | 1975 | 17 | 0.010 |
Why?
| | Erythrocyte Count | 1 | 1975 | 19 | 0.010 |
Why?
| | Radioisotopes | 1 | 1975 | 28 | 0.010 |
Why?
| | Common Bile Duct | 1 | 1975 | 14 | 0.010 |
Why?
| | Selenium | 1 | 1975 | 31 | 0.010 |
Why?
| | Inflammation | 1 | 2005 | 2464 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1984 | 3498 | 0.010 |
Why?
| | Bone Diseases | 1 | 1976 | 57 | 0.010 |
Why?
| | Metabolic Clearance Rate | 2 | 1986 | 102 | 0.010 |
Why?
| | Exons | 1 | 1996 | 301 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 1996 | 373 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1976 | 158 | 0.010 |
Why?
| | Laparotomy | 1 | 1975 | 101 | 0.010 |
Why?
| | Leukocytes | 1 | 1996 | 272 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1975 | 150 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1975 | 292 | 0.010 |
Why?
| | Hemoglobins | 1 | 1976 | 308 | 0.010 |
Why?
| | Pituitary Function Tests | 1 | 1993 | 3 | 0.010 |
Why?
| | Orbit | 1 | 1993 | 52 | 0.010 |
Why?
| | Vitamin D | 1 | 1976 | 340 | 0.010 |
Why?
| | Pituitary Gland | 1 | 1993 | 147 | 0.010 |
Why?
| | Thyrotropin-Releasing Hormone | 2 | 1982 | 12 | 0.010 |
Why?
| | Base Sequence | 1 | 1996 | 2114 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 1997 | 830 | 0.010 |
Why?
| | Infusions, Parenteral | 1 | 1991 | 36 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1996 | 2783 | 0.010 |
Why?
| | Child | 3 | 1996 | 18400 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 1982 | 1846 | 0.010 |
Why?
| | Biopsy | 1 | 1993 | 1024 | 0.010 |
Why?
| | Diabetic Ketoacidosis | 1 | 1991 | 161 | 0.000 |
Why?
| | Liver | 2 | 1986 | 1633 | 0.000 |
Why?
| | Random Allocation | 1 | 1987 | 328 | 0.000 |
Why?
| | Bread | 1 | 1986 | 4 | 0.000 |
Why?
| | Danazol | 1 | 1985 | 2 | 0.000 |
Why?
| | Child, Preschool | 1 | 1979 | 9114 | 0.000 |
Why?
| | Bromocriptine | 1 | 1985 | 26 | 0.000 |
Why?
| | Menstruation | 1 | 1985 | 35 | 0.000 |
Why?
| | Pyridoxine | 1 | 1985 | 28 | 0.000 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1985 | 72 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1976 | 2122 | 0.000 |
Why?
| | Aged, 80 and over | 1 | 1996 | 6306 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1984 | 48 | 0.000 |
Why?
| | Proinsulin | 1 | 1984 | 48 | 0.000 |
Why?
| | Progesterone | 1 | 1985 | 232 | 0.000 |
Why?
| | Psychotherapy | 1 | 1985 | 149 | 0.000 |
Why?
| | Antidepressive Agents | 1 | 1985 | 195 | 0.000 |
Why?
| | Digestive System | 1 | 1983 | 27 | 0.000 |
Why?
| | Estrogens | 1 | 1985 | 312 | 0.000 |
Why?
| | Catecholamines | 1 | 1983 | 94 | 0.000 |
Why?
| | Exophthalmos | 1 | 1982 | 16 | 0.000 |
Why?
| | Kinetics | 1 | 1986 | 1547 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1984 | 1003 | 0.000 |
Why?
| | Chlorpropamide | 1 | 1982 | 1 | 0.000 |
Why?
| | Magnetic Resonance Imaging | 1 | 1993 | 3039 | 0.000 |
Why?
| | Substance Withdrawal Syndrome | 1 | 1984 | 159 | 0.000 |
Why?
| | Calcitonin | 1 | 1982 | 23 | 0.000 |
Why?
| | Thyroidectomy | 1 | 1982 | 62 | 0.000 |
Why?
| | Isotope Labeling | 1 | 1981 | 67 | 0.000 |
Why?
| | Anorexia Nervosa | 1 | 1982 | 63 | 0.000 |
Why?
| | Coronary Circulation | 1 | 1981 | 134 | 0.000 |
Why?
| | Propranolol | 1 | 1981 | 46 | 0.000 |
Why?
| | Alkalosis | 1 | 1980 | 2 | 0.000 |
Why?
| | Amylases | 1 | 1980 | 13 | 0.000 |
Why?
| | Microscopy, Electron | 1 | 1981 | 408 | 0.000 |
Why?
| | Hypertrophy | 1 | 1980 | 109 | 0.000 |
Why?
| | Islets of Langerhans | 1 | 1986 | 728 | 0.000 |
Why?
| | Testosterone | 1 | 1982 | 341 | 0.000 |
Why?
| | Indicators and Reagents | 1 | 1979 | 99 | 0.000 |
Why?
| | Gels | 1 | 1979 | 72 | 0.000 |
Why?
| | Heterozygote | 1 | 1979 | 250 | 0.000 |
Why?
| | Pedigree | 1 | 1979 | 460 | 0.000 |
Why?
| | Heart | 1 | 1981 | 613 | 0.000 |
Why?
| | Kidney | 1 | 1984 | 1182 | 0.000 |
Why?
| | Depression | 1 | 1985 | 1133 | 0.000 |
Why?
| | Genetic Variation | 1 | 1979 | 868 | 0.000 |
Why?
|
|
Falko's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|